INOmax: Uses, Dosage & Side Effects

What Is INOmax and What Is It Used For?

INOmax contains the active substance nitric oxide (NO), a colorless gas that is a naturally occurring signaling molecule in the human body. Nitric oxide plays a critical role in regulating vascular tone, particularly in the pulmonary circulation. When administered by inhalation, nitric oxide reaches the alveoli (air sacs) of the lungs and diffuses across the alveolar-capillary membrane into the underlying smooth muscle cells of the pulmonary blood vessels. There, it activates the enzyme soluble guanylate cyclase (sGC), which catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). The resulting increase in intracellular cGMP leads to relaxation of the vascular smooth muscle, causing vasodilation specifically in the pulmonary vasculature.

The selective nature of inhaled nitric oxide is one of its most important pharmacological properties. Because the gas is delivered directly to the lungs, it preferentially dilates blood vessels in ventilated (aerated) lung regions. This selective action on the pulmonary vasculature means that INOmax reduces pulmonary artery pressure and pulmonary vascular resistance without causing significant systemic hypotension. Furthermore, by directing blood flow to well-ventilated areas of the lung, INOmax improves ventilation-perfusion (V/Q) matching, which is the relationship between airflow and blood flow in the lungs. This improved V/Q matching results in better oxygenation of the blood, which is the primary therapeutic goal in patients with PPHN.

Once inhaled nitric oxide enters the bloodstream, it is rapidly inactivated by binding to hemoglobin. Nitric oxide combines with oxyhemoglobin to form methemoglobin and nitrate (NO3−), and with deoxyhemoglobin to form nitrosylhemoglobin, which is subsequently oxidized to methemoglobin. This rapid inactivation in the blood is the reason why the vasodilatory effects of inhaled nitric oxide are confined to the pulmonary circulation and do not extend to the systemic circulation. The methemoglobin formed is converted back to functional hemoglobin by the enzyme methemoglobin reductase (NADH-cytochrome b5 reductase), a process that is highly efficient in adults but may be less robust in neonates, which is why methemoglobin levels must be carefully monitored during INOmax therapy.

Persistent pulmonary hypertension of the newborn (PPHN) is a serious condition that occurs in approximately 1–2 per 1,000 live births. In the normal transition from fetal to neonatal life, the pulmonary vascular resistance drops dramatically at birth as the lungs inflate with air and begin gas exchange. In PPHN, this normal transition fails to occur, and the pulmonary vascular resistance remains abnormally elevated. This results in right-to-left shunting of deoxygenated blood through the patent ductus arteriosus and/or the foramen ovale, bypassing the lungs. The consequence is severe hypoxemia (low blood oxygen levels) that can lead to tissue hypoxia, organ damage, and death if untreated. PPHN can occur as a primary condition (idiopathic PPHN), or secondary to conditions such as meconium aspiration syndrome, respiratory distress syndrome, pneumonia, sepsis, congenital diaphragmatic hernia, or perinatal asphyxia.

The pivotal clinical trial supporting the approval of INOmax was the NINOS (Neonatal Inhaled Nitric Oxide Study) trial, a large multicenter, randomized, double-blind, placebo-controlled study published in the New England Journal of Medicine in 1997. This trial enrolled 235 term and near-term neonates (≥34 weeks gestational age) with hypoxic respiratory failure and evidence of PPHN. Neonates were randomized to receive either inhaled nitric oxide at 20 ppm or nitrogen gas (placebo) delivered through the ventilator circuit. The primary endpoint was the combined incidence of death or the need for ECMO.

The results of the NINOS trial were landmark: INOmax significantly reduced the combined endpoint of death or need for ECMO. Specifically, 46% of patients in the control group required ECMO or died, compared with 30% in the INOmax group—a relative risk reduction of approximately 40%. This meant that for every 6 patients treated with INOmax, one patient was spared from ECMO or death. The improvement in oxygenation was rapid, typically occurring within 30 minutes to a few hours of initiating therapy. Subsequent studies, including the CINRGI trial, confirmed these findings and demonstrated that INOmax improved oxygenation while reducing the need for ECMO without increasing the risk of significant adverse events.

INOmax was first approved by the U.S. Food and Drug Administration (FDA) in December 1999 for the treatment of term and near-term (≥34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for ECMO. It was subsequently approved by the European Medicines Agency (EMA) and is now available in more than 70 countries worldwide. INOmax remains the only FDA-approved inhaled nitric oxide product for this indication and has become an essential component of neonatal intensive care units globally.

What Should You Know Before Using INOmax?

Contraindications

The primary contraindication to INOmax use is in neonates who are known to be dependent on right-to-left shunting of blood through the ductus arteriosus. In certain congenital heart defects, such as critical coarctation of the aorta, interrupted aortic arch, or hypoplastic left heart syndrome, blood flow from the right side of the heart to the systemic circulation through the ductus arteriosus is essential for survival. INOmax, by reducing pulmonary vascular resistance and increasing pulmonary blood flow, can decrease the right-to-left ductal shunt that these patients depend upon, potentially leading to cardiovascular collapse, severe systemic hypotension, and death.

Before initiating INOmax therapy, echocardiography should be performed to rule out ductal-dependent congenital heart disease. This is a critical step in the clinical evaluation of any neonate presenting with cyanosis and hypoxemia, as the presentation of PPHN can mimic that of cyanotic congenital heart disease. If there is any uncertainty about the diagnosis, INOmax should not be started until ductal-dependent cardiac disease has been excluded.

INOmax is also contraindicated in patients with known hypersensitivity to nitric oxide or nitrogen, although true allergic reactions to these simple gas molecules are exceedingly rare. Additionally, INOmax should not be used in premature neonates born before 34 weeks of gestation unless as part of a clinical trial, as studies have not demonstrated a clear benefit in this population, and there may be an increased risk of intracranial hemorrhage.

Warnings and Precautions

Several important precautions must be observed when using INOmax:

• Methemoglobinemia: Nitric oxide oxidizes hemoglobin to methemoglobin, which cannot carry oxygen effectively. Methemoglobin levels should be measured within 4–8 hours after initiating INOmax therapy and periodically thereafter using co-oximetry. If methemoglobin levels exceed 5%, the dose of INOmax should be reduced. If levels reach or exceed 7%, INOmax should be discontinued. Neonates are particularly susceptible to methemoglobinemia due to their higher proportion of fetal hemoglobin, lower methemoglobin reductase activity, and higher metabolic rate.
• Nitrogen dioxide (NO2) formation: Nitric oxide reacts with oxygen to form nitrogen dioxide, a toxic gas that can cause airway inflammation, pulmonary edema, and worsening of respiratory function. The concentration of NO2 in the breathing circuit must be monitored continuously and should remain below 1 ppm (ideally below 0.5 ppm). Higher inspired oxygen concentrations and higher NO doses increase NO2 formation. The delivery system must be configured to minimize contact time between NO and O2 before the gas mixture reaches the patient.
• Bleeding risk: Nitric oxide inhibits platelet aggregation and adhesion in vitro. While clinically significant bleeding attributable to INOmax has not been clearly established in controlled trials, caution is advised in patients with pre-existing bleeding disorders or thrombocytopenia. Platelet counts and bleeding parameters should be monitored.
• Heart failure: In patients with pre-existing left ventricular dysfunction, the reduction in pulmonary vascular resistance caused by INOmax can increase pulmonary blood flow and left atrial pressure, potentially precipitating or worsening pulmonary edema. Careful hemodynamic assessment including echocardiography is recommended before and during treatment.
• Delivery system requirements: INOmax must only be administered using an approved nitric oxide delivery system (such as the INOmax DSIR or INOmax DS system) that provides precise, calibrated dosing and continuous monitoring of NO, NO2, and FiO2 concentrations. Improvised or non-calibrated delivery systems should never be used due to the risk of inaccurate dosing and toxic NO2 exposure.

Pregnancy and Breastfeeding

INOmax is indicated for use in neonates, not in adult patients including pregnant or breastfeeding women. However, inhaled nitric oxide has been used off-label in pregnant women with severe pulmonary hypertension, particularly in the peripartum period. In such cases, the decision to use INOmax should be made by experienced clinicians after careful consideration of the potential benefits and risks. Animal reproductive toxicology studies have not revealed teratogenic effects, but data in human pregnancy are limited.

Healthcare workers who are pregnant or breastfeeding and are involved in administering INOmax should follow standard occupational exposure guidelines. The U.S. Occupational Safety and Health Administration (OSHA) permissible exposure limit for nitric oxide is 25 ppm (8-hour time-weighted average). Proper ventilation and gas scavenging systems in the ICU minimize worker exposure to negligible levels.

Special Populations

INOmax has been studied most extensively in term and near-term neonates (≥34 weeks gestational age) with PPHN. Its use in preterm neonates (<34 weeks) has been investigated in multiple randomized controlled trials, but these studies have not demonstrated a consistent benefit in preventing bronchopulmonary dysplasia (BPD) or improving survival. The American Academy of Pediatrics (AAP) has issued a policy statement concluding that routine use of inhaled nitric oxide in preterm infants with respiratory failure is not recommended. Off-label use in adults with acute respiratory distress syndrome (ARDS) and other forms of pulmonary hypertension has been reported but remains investigational and is not an approved indication.

How Does INOmax Interact with Other Drugs?

While INOmax is delivered as an inhaled gas and its primary site of action is the pulmonary vasculature, there are several clinically relevant drug interactions that healthcare professionals must be aware of. Unlike oral medications that are metabolized by hepatic cytochrome P450 enzymes, the interaction profile of inhaled nitric oxide relates primarily to its pharmacodynamic effects on vascular tone, hemoglobin oxidation, and platelet function.

Understanding these interactions is critical in the NICU setting, where patients frequently receive multiple medications concurrently. The following table summarizes the most important drug interactions with INOmax:

Major Interactions

The most clinically significant interactions are with nitric oxide donor compounds and agents that cause methemoglobinemia. Nitric oxide donors such as sodium nitroprusside, nitroglycerin, and isosorbide dinitrate all release nitric oxide either directly or through enzymatic conversion. When used concurrently with INOmax, the cumulative nitric oxide exposure can lead to excessive vasodilation (potentially causing systemic hypotension even though INOmax alone primarily affects the pulmonary circulation) and accelerated methemoglobin formation. In the neonatal population, these agents are rarely used concurrently, but awareness of this interaction is important for clinical decision-making.

Prilocaine, a local anesthetic commonly found in EMLA cream (lidocaine-prilocaine topical combination), is a well-known methemoglobin-inducing agent. Neonates are particularly susceptible to prilocaine-induced methemoglobinemia due to their lower methemoglobin reductase activity and higher proportion of fetal hemoglobin. The concurrent use of EMLA cream and INOmax should be avoided. If a topical anesthetic is required for procedures during INOmax therapy, lidocaine alone (which has a much lower methemoglobinemia risk) should be used as an alternative.

Minor and Intentional Interactions

Phosphodiesterase-5 (PDE-5) inhibitors, particularly sildenafil, represent an important and unique interaction with INOmax. These agents inhibit the enzyme PDE-5, which is responsible for the degradation of cGMP in pulmonary vascular smooth muscle cells. By preventing cGMP breakdown, PDE-5 inhibitors amplify and prolong the vasodilatory effects of nitric oxide. While this interaction can potentially cause excessive pulmonary vasodilation and hypotension, it is sometimes exploited therapeutically to facilitate weaning from INOmax. The addition of oral or intravenous sildenafil before or during the weaning process can help prevent rebound pulmonary hypertension and enable successful discontinuation of INOmax therapy. This strategy has been adopted in many NICUs worldwide and is supported by clinical evidence.

Prostacyclin analogs (epoprostenol, iloprost, treprostinil) work through a complementary signaling pathway (cyclic AMP rather than cyclic GMP). When used in combination with INOmax, the additive pulmonary vasodilatory effects may be beneficial in severe or refractory pulmonary hypertension, but careful hemodynamic monitoring is required to avoid systemic hypotension. This combination approach is primarily used in severe cases that do not respond adequately to INOmax alone.

What Is the Correct Dosage of INOmax?

INOmax dosing is fundamentally different from most other medications because it is delivered as an inhaled gas measured in parts per million (ppm) rather than in milligrams or units per body weight. The concentration of nitric oxide in the inspired gas mixture is precisely controlled by a specialized electronic delivery system that interfaces with the patient's ventilator circuit. The dosing regimen is relatively straightforward, but the initiation, maintenance, and especially the weaning phases require careful clinical judgment and continuous monitoring.

Term and Near-Term Neonates (PPHN)

Dosing Summary by Patient Group

Interrupted Delivery

Unlike oral or injectable medications where a missed dose can simply be taken later, interruption of INOmax delivery can have immediate and potentially life-threatening consequences. Any interruption in INOmax delivery, even for brief periods such as during patient transport, suctioning, or ventilator circuit changes, can trigger rebound pulmonary hypertension with rapid desaturation and hemodynamic instability. Healthcare teams must have backup delivery systems immediately available, and protocols for maintaining nitric oxide delivery during all clinical activities (including transport, procedures, and equipment changes) must be in place.

Many NICUs use portable or battery-operated INOmax delivery systems that can maintain therapy during intrahospital transport (e.g., to radiology for imaging). The INOmax DSIR system includes a built-in backup cylinder and alarm systems that alert clinicians to any interruption in delivery. If delivery is inadvertently interrupted, it should be restored as quickly as possible and the patient should be closely monitored for signs of clinical deterioration.

Overdose

Overdose with INOmax manifests primarily as elevated methemoglobin levels, which can be detected by co-oximetry or pulse oximetry (although standard pulse oximeters may give falsely reassuring readings in the presence of significant methemoglobinemia). At methemoglobin levels above 5%, oxygen delivery to tissues is impaired, and levels above 20–30% can be life-threatening.

In the event of suspected overdose (delivery of nitric oxide concentrations significantly above 20 ppm, or methemoglobin levels exceeding 7%), the following steps should be taken: immediately reduce the INOmax dose (but do not discontinue abruptly), increase the FiO2 to maximize oxygen delivery, and administer methylene blue (1–2 mg/kg intravenously over 5 minutes) as an antidote for severe methemoglobinemia. Methylene blue acts as an electron carrier in the methemoglobin reductase pathway, accelerating the conversion of methemoglobin back to functional hemoglobin. Blood transfusion with packed red blood cells may be necessary in severe cases to restore oxygen-carrying capacity.

Exposure to extremely high concentrations of nitric oxide gas (>200 ppm) can cause acute lung injury through the formation of toxic nitrogen dioxide. This scenario would typically require a delivery system malfunction and should be prevented by the alarm systems and redundant safety features of approved INOmax delivery devices.

What Are the Side Effects of INOmax?

INOmax is administered in a closely monitored intensive care environment, which allows for rapid detection and management of adverse effects. The safety profile of inhaled nitric oxide has been extensively studied in multiple randomized controlled trials involving thousands of neonates. Most adverse effects are related to the known pharmacological properties of nitric oxide (methemoglobin formation, effects on platelet function, and rebound hemodynamic changes upon withdrawal) rather than idiosyncratic drug reactions.

It is important to distinguish between adverse effects directly attributable to INOmax and those related to the underlying condition being treated (PPHN and associated hypoxic respiratory failure), as many of these patients are critically ill and receiving multiple concurrent therapies. The following frequency classifications are based on data from controlled clinical trials and post-marketing surveillance:

Long-term follow-up studies of neonates treated with INOmax for PPHN have not identified significant adverse neurodevelopmental outcomes compared with control groups. The NINOS trial included follow-up assessments at 18–24 months corrected age, which showed comparable neurodevelopmental outcomes between the INOmax and placebo groups. This is reassuring, as it suggests that INOmax therapy during the neonatal period does not cause lasting harm to the developing brain, although the underlying condition (PPHN and associated hypoxemia) itself is associated with neurodevelopmental risk.

How Should You Store INOmax?

INOmax is supplied as a compressed gas in aluminum cylinders at a concentration of 800 ppm nitric oxide in nitrogen. Because it is a compressed gas, the storage and handling requirements differ significantly from those of conventional pharmaceutical products such as tablets, capsules, or solutions. Proper storage and handling are essential for both patient safety and the safety of healthcare workers.

The following storage conditions must be maintained for INOmax gas cylinders:

• Temperature: Store at temperatures between 10–40 °C (50–104 °F). Extreme temperatures should be avoided, as excessive heat can increase the pressure inside the cylinder and pose a safety hazard, while very low temperatures can affect the gas delivery characteristics.
• Orientation: Cylinders must be stored upright and secured in an approved cylinder rack or stand to prevent falling. A falling cylinder can cause injury to personnel and damage to the valve, potentially releasing compressed gas.
• Ventilation: Store in a well-ventilated area. Although the cylinders are sealed, any inadvertent gas release should be dispersed safely. Do not store in enclosed, unventilated spaces.
• Separation from hazards: Keep away from heat sources, open flames, sparks, and ignition sources. Although nitric oxide itself is not flammable, it supports combustion under certain conditions. Keep cylinders away from oil, grease, and other oxidizable materials.
• Incompatible materials: Do not allow INOmax to come into contact with oils, greases, or petroleum-based lubricants, as these can react violently with oxidizing gases.
• Expiration: Do not use INOmax after the expiration date printed on the cylinder label. Return expired cylinders to the supplier for disposal.
• Cylinder identification: INOmax cylinders are marked with specific labeling and color coding (typically turquoise shoulder with white body in the EU, or specific labeling in the US). Always verify the cylinder identity before connecting to the delivery system.

In the hospital setting, INOmax cylinders are typically stored in a designated gas storage area near the NICU or in the patient's room, connected to the delivery system and ready for immediate use. Backup cylinders should always be available in the unit to ensure uninterrupted therapy. The INOmax delivery system includes cylinder pressure gauges and low-pressure alarms to alert staff when a cylinder is running low and needs to be replaced.

Disposal of empty or partially used INOmax cylinders must follow local regulations for compressed gas cylinders and medical waste. Cylinders should be returned to the supplier or designated waste management contractor. They should never be disposed of in regular waste streams or incinerated.

What Does INOmax Contain?

INOmax has an exceptionally simple composition compared with most pharmaceutical products. It consists of only two components:

• Active substance: Nitric oxide (NO), 800 ppm (0.08% by volume). Nitric oxide is a small diatomic molecule consisting of one nitrogen atom and one oxygen atom. It has a molecular weight of 30.01 g/mol. At room temperature and atmospheric pressure, it is a colorless gas with no significant odor at therapeutic concentrations. Nitric oxide is the endogenous signaling molecule responsible for smooth muscle relaxation in blood vessels, originally identified as “endothelium-derived relaxing factor” (EDRF) by Robert F. Furchgott, Louis J. Ignarro, and Ferid Murad, who were awarded the Nobel Prize in Physiology or Medicine in 1998 for their discoveries concerning nitric oxide as a signaling molecule in the cardiovascular system.
• Carrier gas: Nitrogen (N2), making up the remaining 99.92% of the gas mixture. Nitrogen is an inert gas that serves as a stable and non-reactive carrier for the nitric oxide. Medical-grade nitrogen is used to ensure purity and safety.

INOmax does not contain any preservatives, stabilizers, propellants, excipients, or other additives. The simplicity of the formulation eliminates the potential for allergic reactions to excipients, which can be a concern with more complex pharmaceutical formulations. The gas mixture is stable within the sealed aluminum cylinder throughout its shelf life.

When INOmax is delivered to the patient, the delivery system precisely mixes the concentrated 800 ppm nitric oxide/nitrogen mixture with the ventilator gas (which contains oxygen and possibly air) to achieve the prescribed concentration (typically 20 ppm) at the point of delivery. This dilution step is critical, as the 800 ppm stock concentration is too high for direct patient delivery. The delivery system performs this dilution automatically and monitors the resulting NO concentration, NO2 concentration, and FiO2 in real time.

It is worth noting that INOmax is the only pharmaceutical-grade inhaled nitric oxide product with regulatory approval in most countries. The use of “pharmacy-compounded” or “industrial-grade” nitric oxide gas for clinical use is not recommended, as these products may contain impurities (including higher levels of nitrogen dioxide and other contaminants) and are not manufactured to pharmaceutical standards. The quality, purity, and consistency of INOmax are assured through rigorous manufacturing processes and regulatory oversight.